Cargando…

A 12-immune cell signature to predict relapse and guide chemotherapy for stage II colorectal cancer

The management of stage II colorectal cancer is still difficult. We aimed to construct a new immune cell-associated signature for prognostic evaluation and guiding chemotherapy in stage II colorectal cancer. We used the “Cell Type Identification by Estimating Relative Subsets of RNA Transcripts” (CI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Xianglong, Zhu, Xiaoqiang, Meng, Wenying, Bai, Shiguang, Shi, Min, Xiang, Shihao, Zhao, Chen, Wang, Yugang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585080/ https://www.ncbi.nlm.nih.gov/pubmed/32855365 http://dx.doi.org/10.18632/aging.103707

Ejemplares similares

A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients
por: Zhu, Xiaoqiang, et al.
Publicado: (2021)

Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer
por: Feng, Yang, et al.
Publicado: (2019)

The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study
por: Roberto, Michela, et al.
Publicado: (2022)

A novel 9-gene signature for the prediction of postoperative recurrence in stage II/III colorectal cancer
por: Xin, Cheng, et al.
Publicado: (2023)

Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials
por: Zhu, Xiaoqiang, et al.
Publicado: (2016)

Recurrence‐associated gene signature optimizes recurrence‐free survival prediction of colorectal cancer
por: Tian, Xianglong, et al.
Publicado: (2017)

A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources
por: Zhao, Wenyuan, et al.
Publicado: (2016)

A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer
por: Cao, Bangrong, et al.
Publicado: (2017)

High-throughput proteomics profiling-derived signature associated with chemotherapy response and survival for stage II/III colorectal cancer
por: Ye, Shu-Biao, et al.
Publicado: (2023)

Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse
por: Al-Temaimi, Rabeah A., et al.
Publicado: (2016)

Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes
por: Gao, Zhenyan, et al.
Publicado: (2021)

An immune, stroma, and epithelial–mesenchymal transition‐related signature for predicting recurrence and chemotherapy benefit in stage II–III colorectal cancer
por: Cai, Du, et al.
Publicado: (2023)

Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients
por: Ji, Dengbo, et al.
Publicado: (2018)

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
por: Chen, Yuanyuan, et al.
Publicado: (2022)

Copy‐number intratumor heterogeneity increases the risk of relapse in chemotherapy‐naive stage II colon cancer
por: Lahoz, Sara, et al.
Publicado: (2022)

A network‐based predictive gene expression signature for recurrence risks in stage II colorectal cancer
por: Yang, Wen‐Jing, et al.
Publicado: (2019)

N-Glycomic Signature of Stage II Colorectal Cancer and Its Association With the Tumor Microenvironment
por: Boyaval, Fanny, et al.
Publicado: (2021)

The development and validation of a CT-based radiomics signature for the preoperative discrimination of stage I-II and stage III-IV colorectal cancer
por: Liang, Cuishan, et al.
Publicado: (2016)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

Effect of Adjuvant Chemotherapy on Elderly Stage II High-Risk Colorectal Cancer Patients
por: Lee, Yujin, et al.
Publicado: (2021)

A seven-gene signature predicts overall survival of patients with colorectal cancer
por: Chen, Huarong, et al.
Publicado: (2016)

The aging-related risk signature in colorectal cancer
por: Yue, Taohua, et al.
Publicado: (2021)

Long non‐coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1
por: Wu, Qiong, et al.
Publicado: (2018)

Predictive Models of Adjuvant Chemotherapy for Patients with Stage II Colorectal Cancer: A Retrospective Study
por: Wei, Bo, et al.
Publicado: (2017)

Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study
por: Jalaeikhoo, Hasan, et al.
Publicado: (2019)

Identification of Prognostic Gene Signatures by Developing a scRNA-Seq-Based Integration Approach to Predict Recurrence and Chemotherapy Benefit in Stage II–III Colorectal Cancer
por: Wang, Zixuan, et al.
Publicado: (2022)

CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
por: Song, Bolin, et al.
Publicado: (2023)

Development and validation of a collagen signature to predict the prognosis of patients with stage II/III colorectal cancer
por: Dong, Shumin, et al.
Publicado: (2023)

ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study
por: Huang, Ming-Yii, et al.
Publicado: (2008)

Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II
por: Horvat, Matej, et al.
Publicado: (2016)

A long non-coding RNA signature to improve prognosis prediction of gastric cancer
por: Zhu, Xiaoqiang, et al.
Publicado: (2016)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Correlation between immune signature and high‐density lipoprotein cholesterol level in stage II/III colorectal cancer
por: Wang, Yun, et al.
Publicado: (2019)

Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
por: Rokavec, Matjaz, et al.
Publicado: (2023)

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer
por: Huang, Lei, et al.
Publicado: (2023)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
por: Kim, Jung Ho, et al.
Publicado: (2015)

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
por: Iveson, Timothy J., et al.
Publicado: (2021)

Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer
por: Millen, Rosemary, et al.
Publicado: (2016)

Metabolomic and exome sequence analysis reveal novel molecular signatures associated with colorectal cancer relapse
por: Gauba, Robinder, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_60mqq1203upgm16mlm4pjkc0de